Loading...
•
Dec 31, 2022
Tectonic Q4 2022 Earnings Report
AVROBIO reported financial results for the fourth quarter and year ended Dec. 31, 2022 and provided a business update.
Key Takeaways
AVROBIO reported a net loss of $25.0 million for the fourth quarter of 2022. As of Dec. 31, 2022, AVROBIO had $92.6 million in cash and cash equivalents.
Following positive regulatory feedback, AVROBIO plans to initiate registrational global Phase 2/3 clinical trial for Gaucher disease type 3 (GD3) in second half 2023, subject to regulatory alignment
Patient dosing completed in collaborator-sponsored Phase 1/2 clinical trial for cystinosis; plan to initiate late-stage clinical trial activities in second half 2023, subject to regulatory alignment
Plan to initiate collaborator-sponsored Phase 1/2 clinical trial for mucopolysaccharidosis type II (MPS-II), or Hunter syndrome, in 2023
AVROBIO expects its cash and cash equivalents as of Dec. 31, 2022, will enable AVROBIO to fund its operating expenses and capital expenditure requirements into the first quarter of 2024.